🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us at the Patient Recruitment for Rare Disease Trials Summit December 10-12 in Boston! Our very own Kelli Wright, Director of Patient Advocacy, will be sharing examples on how to include patient input into clinical trial design at any stage of your program. Learn more:

We're proud to partner with Children’s Brain Tumor Network in our shared commitment to developing new treatments for children with brain tumors. Read more: prn.to/4iIe3XJ

We’re looking forward to attending the J.P. Morgan Healthcare Conference. Dr. Jeremy Bender, CEO, will present on Monday, January 13, at 3:45 PM PT. A live audio webcast of the presentation will be available here: bit.ly/3UMCys7 Learn more: bit.ly/3ZJjr3Y

We are excited to share our recently published manuscript in Neuro-Oncology, which details radiographic and visual response to tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. These findings from a post-hoc analysis contribute to our

We’re looking forward to presenting at #JPM25 today. Please join us at 3:45 PM PT in person or by live audio webcast here: bit.ly/4h3Bn0m Read the full press release: bit.ly/3Wcr8yU

As we step into the new year, our commitment to delivering first- or best-in-class medicines for children and adults remains as steadfast as ever. At Day One, every decision we make is guided by our mission to bring hope to those facing cancer and other serious diseases.

Diagnosed with pediatric low-grade glioma (pLGG) at 11 years old, Bradon reflects on his experience navigating the challenges of his diagnosis and treatment journey. Read his full story here: bit.ly/3WIDUW8

Tomorrow is International Childhood Cancer Day, a time to recognize the children and families impacted by cancer and the urgent need for better, targeted treatments, sooner. Too often, children wait years for the same breakthrough medicines adults receive. At Day One, we’re

On National Caregivers Day, we honor the unwavering strength of those who care for loved ones- especially the parents and family members who navigate the challenges of childhood brain tumors. For Anna, caregiving became a lifelong journey the day her son, Bradon, was diagnosed

Day One reports fourth quarter and full year 2024 financial results. Read more: bit.ly/4gRUUAk

It was an honor to attend the Team Jack Gala and support the Team Jack Foundation in their mission to raise awareness and funds to fight pediatric brain cancer. At Day One, we share Team Jack's drive to fight for a world without childhood brain cancer. We strive to disrupt the

Christa Kerkorian, VP Patient Advocacy at Day One, will be speaking at the #PatientsAsPartners2025 conference on 3/17. She will discuss how Day One, patient advocates, and academia partnered to co-create a new framework for multistakeholder collaboration in pediatric cancer and

We're honored to be named a finalist in the "Excellence in Rare Drug Development" at the 2025 Citeline Awards! This recognition reflects our team's dedication and the urgency that drives us every day to get better, targeted medicines faster to patients of all ages who urgently

Join us at the AACR Annual Meeting 2025 in Chicago! #AACR25 abstracts include preclinical data on sequencing tovorafenib and MEK inhibitor therapy in BRAF fusion-driven tumor models and a Trial in Progress poster on the ongoing phase 1 trial of the PTK-7 targeted antibody drug

Every day, children and families face the life-changing reality of a brain tumor diagnosis, the most common solid tumor in pediatric patients and some of the hardest to treat. During #BrainTumorAwarenessMonth, we’re committed to shining a light on the profound impact brain tumors

Day One reports first quarter 2025 financial results. Read more: bit.ly/3Smr6Sr

The Day One team is excited to be at the 2025 American Society of Pediatric Hematology/Oncology Conference in Louisville this week! Stop by our booth 113 to hear how we're redefining what's possible for people of all ages living with cancer. #ASPHO2025 Learn more about our mission here: bit.ly/4gsrd8W

We're gearing up for this year's ASCO Annual Meeting and we're excited to see everyone in Chicago! #ASCO25 abstracts include data from the FIREFLY-1 study in pediatric low-grade glioma (pLGG): 📌Abstract 10029 on growth recovery in patients with BRAF-altered pLGG after

Day One will be participating in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami on Tuesday, June 10th. Learn more about our pipeline and commitment to developing and commercializing targeted therapies for people of all ages living with

We’re thrilled to announce that Michael Vasconcelles, M.D., has joined Day One as Head of Research & Development (R&D). Mike brings more than 25 years of experience in oncology research and development as an academic hematologist/oncologist and as an industry leader in large